Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

United Therapeutics Corp. UTHR

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$3.2B
▲ 10.6% YoY
$1.3B
▲ 11.7% YoY
$1.0B
▼ 3.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

United Therapeutics Corporation markets and sells commercial therapies in the United States to treat pulmonary arterial hypertension, including Tyvaso DPI, Tyvaso Inhalation Solution, Remodulin, Orenitram, and Adcirca. In the United States, it also markets and sells an oncology product, Unituxin (dinutuximab) Injection, approved by the FDA for the treatment of high-risk neuroblastoma. Its wholly-owned subsidiary, Lung Bioengineering Inc., provides commercial ex vivo lung perfusion services on a fee-for-service basis to transplant centers through dedicated facilities in Silver Spring, Maryland, and Jacksonville, Florida, using the XPS System. As of December 31, 2025, the company had approximately 1,400 employees working across 15 locations worldwide. Martine Rothblatt founded United Therapeutics in 1996 and has served as its Chairperson and Chief Executive Officer since its inception.

Written from the business description in UNITED THERAPEUTICS Corp's annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth

USD 3.2B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 3.2 · Net income 1.3
2B3B
2008201120142017202020232025
Compound annual growth
+18.0%
+16.5%
+8.1%
+11.9%
+22.4%
+22.9%
+19.3%
+8.2%
+20.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +16.5% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

42 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 46.9% · Net 41.9%
20%40%60%-10%-20%
200820162025
ROE
FY2025 · ROE 19.7%
20%40%-5%
200820162025
Three returns, three denominators.

Each USD of equity produced 20 cents of profit this year.

Cash & shareholders

USD 826.1M
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 1.0
0.5B1.0B-0.1B-0.3B
200820162025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 826.1
300M600M-40M-80M
201120132015201720232025

USD 826.1M in buybacks — 62% of the year's profit went back to shareholders.

Total assetsUSD 7.9B
EquityUSD 7.1B
CashUSD 1.6B
Current ratio6.60×

Equity funds 90% of total assets.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
UTHR, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B3.22.92.31.91.71.51.41.61.71.61.51.31.10.90.70.60.40.3
Operating income $B1.51.41.21.00.60.6−0.20.80.81.10.70.50.30.40.30.20.0−0.1
EBITDA $B1.61.41.21.00.60.6−0.10.80.81.10.70.60.30.40.30.20.0−0.1
Income tax $B0.40.30.30.20.10.1−0.10.20.40.30.40.20.10.10.10.0−0.0−0.0
Net income $B1.31.21.00.70.50.5−0.10.60.40.70.70.30.20.30.20.10.0−0.0
Free cash flow $B1.01.10.70.70.50.7−0.30.60.40.60.30.30.40.20.20.20.0−0.2
EPS, diluted $27.8624.6419.8115.0010.0611.54−2.3913.399.3115.2512.726.283.285.713.671.780.35−1.08
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————————
ROE %19.719.218.316.612.916.7−3.824.121.141.546.027.214.930.023.813.83.2−8.9
Shares out B0.040.040.050.050.050.040.040.040.040.040.050.050.050.050.050.060.05◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. Four checks were skipped: the balance sheet is not tagged before 2009. One check was skipped: EPS is not tagged before 2008. One check was skipped: revenue is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2008

Share this section

Download image